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ABSTRACT
Arkenberg, Matthew R. M.S., Purdue University, May 2018. Enzymatic Crosslinking
of Dynamic Hydrogels for In Vitro Cell Culture. Major Professor: Chien-Chi Lin.
Stiffening and softening of extracellular matrix (ECM) are critical processes gov-
erning many aspects of biological processes. The most common practice used to in-
vestigate these processes is seeding cells on two-dimensional (2D) surfaces of varying
stiffness. In recent years, cell-laden three-dimensional (3D) scaffolds with controllable
properties are also increasingly used. However, current 2D and 3D culture platforms
do not permit spatiotemporal controls over material properties that could influence
tissue processes. To address this issue, four-dimensional (4D) hydrogels (i.e., 3D
materials permitting time-dependent control of matrix properties) are proposed to
recapitulate dynamic changes of ECM properties. The goal of this thesis was to
exploit orthogonal enzymatic reactions for on-demand stiffening and/or softening of
cell-laden hydrogels. The first objective was to establish cytocompatible hydrogels
permitting enzymatic crosslinking and stiffening using enzymes with orthogonal re-
activity. Sortase A (SrtA) and mushroom tyrosinase (MT) were used sequentially to
achieve initial gelation and on-demand stiffening. In addition, hydrogels permitting
reversible stiffening through SrtA-mediated peptide ligation were established. Specif-
ically, poly(ethylene glycol) (PEG)-peptide hydrogels were fabricated with peptide
linkers containing pendent SrtA substrates. The hydrogels were stiffened through in-
cubation with SrtA, whereas gel softening was achieved subsequently via addition of
SrtA and soluble glycine substrate. The second objective was to investigate the role
of dynamic matrix stiffening on pancreatic cancer cell survival, spheroid formation,
and drug responsiveness. The crosslinking of PEG-peptide hydrogels was dynami-
cally tuned to evaluate the effect of matrix stiffness on cell viability and function.
xvi
Specifically, dynamic matrix stiffening inhibited cell proliferation and spheroid for-
mation, while softening the cell-laden hydrogels led to significant increase in spheroid
sizes. Matrix stiffness also altered the expression of chemoresistance markers and
responsiveness of cancer cells to gemcitabine treatment. markers and responsiveness
of cancer cells to gemcitabine treatment.
11. INTRODUCTION
1.1 Dynamic Biological Processes
ECM stiffening and softening are hallmarks of physiological and pathophysiolog-
ical processes, including cancer progression, tissue fibrosis, and stem cell differenti-
ation [1–3]. Specifically, variation of ECM mechanics could lead to changes in cell
morphologies and behaviors [4, 5], differentiation potentials [6, 7], and protein secre-
tion [8]. Matrix stiffening is caused by increased secretion of ECM (e.g., collagen)
by stromal cells [9–11]. For example, primary human lung fibroblasts produce colla-
gen in response to transforming growth factor beta (TGF-β) treatment [9]. In the
lungs, TGF-β reduces matrix degradation, which leads to the formation of a dense,
fibrotic tissue [9]. Enzymatic crosslinking can also increase matrix stiffness [12, 13].
For example, high expression of lysyl oxidase (LOX) leads to significant crosslinking
between collagen and elastin molecules [12]. On the other hand, cell-mediated matrix
degradation is enhanced via MMP secretion and activation [14]. MMPs target a wide
range of ECM molecules, including proteoglycans, collagen, fibronectin, and laminin.
This degradation leads to matrix softening.
1.1.1 Cancer Progression
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer that has poor
reception to chemotherapeutic agents [15, 16]. PDAC is characterized with a dense
stroma [2] that promotes epithelial-mesenchymal-transition (EMT) and drug resis-
tance [17]. While chemotherapy can effectively reduce the majority of tumor mass
in a variety of cancers, cancer stem cells (CSCs) can survive leading to a generation
of chemotherapeutically resistance cancer cells [18–20]. Matrix stiffening has been
2reported to affect CSC growth and stem cell marker expression [21,22]. For example,
hepatic CSCs expressed higher level of stem cell markers, including CD133, EpCAM,
Nanog, and SOX2. Furthermore, these cells had greater self-renewal and oxaliplatin
resistance [22].
In addition to matrix stiffening, Shin and Mooney reported that matrix soften-
ing could alter mechanosensitivity of myeloid leukemia subtypes to drug actions [23].
Specifically, softening of the ECM enhanced cancer growth and led to increased re-
sistance against cytosine arabinoside, a common leukemia treatment [23]. Kong and
colleagues also demonstrated that matrix softening affects the phenotypes of hepato-
carcinoma cells [8]. They reported that liver cancer cells underwent increased prolif-
eration, downregulation of E-cadherin, and increased sensitivity to chemotherapeutic
in the presence of protease-mediated, gradually softened collagen-based hydrogels.
1.1.2 Fibrosis
Fibrotic tissue is associated with significant deposition and crosslinking of fibrillar
collagen by stromal cells. The generation of fibrotic tissue is further facilitated by
LOX-mediated elastin and collagen crosslinking [3]. These phenomena lead to in-
creased matrix stiffness and signaling events associated with inflammation. Matrix
stiffening is both a hallmark of fibrosis and a significant contributer to its patho-
genesis. Namely, increased matrix stiffening has been reported to enhance TGF-β
response [24]. Additionally, ECM stiffening activates wingless-related integration site
(Wnt) and interleukin signaling pathways [25, 26]. Tschumperlin and colleagues re-
ported that matrix stiffening in fibrotic lung tissue inhibited synthesis of prostaglandin
E(2), an inhibitor of fibrogenesis, indicating an important feedback relationship that
enhances the development of fibrosis [27]. In a recent review, Lampi and Reinhart-
King summarize the efficacy of targeting ECM stiffening and its cellular response [28].
They highlighted the necessity and challenges of targeting downstream signaling
3pathways initiated by matrix stiffening (e.g., TGF-β and Rho/Rho-associated kinase
(ROCK) intercellular signaling).
1.1.3 Stem Cell Differentiation
In addition to tumor progression and tissue fibrosis, Discher and colleagues re-
ported that the mechanical properties of a stem cell niche play a significant role in di-
recting the differentiation of mesenchymal stem cells (MSCs) into neurons, myocytes,
and osteoblasts [29]. Culturing MSCs on collagen matrices with low (0.1-1kPa),
medium (8-17 kPa), and high (25-40 kPa) stiffness led to phenotypic responses akin
to neurogenic, myogenic, and osteogenic lineages, respectively [29]. Similarly, Pros-
per and colleagues demonstrated that seeding induced pluripotent stem cells (iPSCs)
on fibronectin- or collagen-coated polyacrylamide (pAA) gels with different elastic
moduli (i.e., 0.6, 14, and 50 kPa) lead to the expression of tissue specific markers [1].
However, it is important to note that these studies were performed on two-dimensional
2D substrates that do not fully recapitulate the 3D stem cell niche.
Many hydrogels have been designed to investigate the role of matrix stiffness on
stem cell expansion and differentiation. For example, Lutolf and colleagues demon-
strated the role of mechanically dynamic environments on differentiation and organoid
formation of intestinal stem cells (ISCs) [6]. Specifically, stiff matrices containing
fibronectin-derived peptide, RGD, were required for ISC expansion through yes-
associated protein 1 (YAP) pathway. On the other hand, differentiation of ISCs
into intestinal tissues required soft matrices and laminin-based adhesion. In addition,
Shakesheff et al. reported that simultaneous alginate to collagen matrix switching
and matrix softening decreased iPSC self-renewal and promoted differentiation into
the three germ layers [30].
41.2 Engineering Strategies to Matrix Stiffening/Softening
Dynamic ECM-mimetic hydrogels with spatiotemporally tunable properties can
facilitate research regarding cancer progression, fibrosis, stem cell fate, and many
other biological processes. Generally, dynamic hydrogels permit time-dependent con-
trol of matrix properties (e.g., matrix stiffness). These hydrogels permit secondary
crosslinking [31–34], site-specific degradation [35–38], or reversible crosslinking [39–42]
upon exposure to an external stimulus (e.g., light, enzymes, or temperature) (Fig-
ure 1.1). Biomimetic hydrogels that afford temporal tunability of matrix properties
are uniquely situated to elucidate many cellular processes. Synthetic approaches are
particularly advantageous as simple, external stimuli can be exploited to permit user
defined, on-demand matrix modification. However, stimuli such as Ultraviolet (UV)-
light or heat may not be desirable. Additionally, these techniques could be improved
to permit stiffening/softening with physiological timescales to mimic both short and
long-term ECM modification.
5Fig. 1.1. Schematic representation of dynamic hydrogels (A) irreversibly stiffened,
(B) irreversibly softened, and (C) reversibly stiffened.
1.2.1 Matrix Stiffening
Utilizing the secondary crosslinking concept, Burdick and colleagues designed
methacrylate-functionalized hyaluronic acid (MeHA) hydrogels with tunable prop-
erties [31]. Hydrogels were initially crosslinked by methacrylated hyaluronic acid and
6thiol-based crosslinker (e.g., dithiothreitol (DTT) with an off-stoichiometric ratio)
via Michael-type addition. Light-and-radical-mediated chain growth polymerization
of the remaining methacrylates was utilized to achieve matrix stiffening. In another
example, Suggs et al. fabricated alginate hydrogels loaded with temperature-sensitive
liposomes containing calcium ions and gold nanorods [32]. Upon infrared radiation
(IR)-mediated heating of the gold nanorods, the liposomes were ruptured leading to
release of calcium ions and further crosslinking of the alginate. Although this system
afforded control of matrix stiffness spatiotemporally, the heat generated from IR ir-
radiation may not be suitable for matrix stiffening. Gyarmati and Szilagyi reported
that disulfide bond formation could be used to stiffen of hydrogels [33]. However, this
approach may destabilize critical proteins and does not afford stringent control over
the magnitude of stiffening.
1.2.2 Matrix Softening
Matrix softening typically occurs through hydrolytic [35, 36, 43] or enzymatic
degradation [35, 38, 44]. For example, Metters and Hubbell reported the degrada-
tion kinetics of hydrogels containing hydrotically labile thioether-ester linkages [43].
A statistical-co-kinetic model was established to verify the hydrolytic degradation
mechanism. Burdick and colleagues developed methacrylated hyaluronic acid hydro-
gels that contained both hydrolytically stable and degradable crosslinks [35]. Hy-
drolytically stable DTT and degradable pentaerythritol tetrakis(mercaptoacetate)
(PETMA) were used to consume 20% and 65% of available methacryltes to per-
mit partial degradation of hydrogels. Utilizing this system, it was demonstrated that
stellate cells in a gradually softened environment (from 20 kPa to 3 kPa) reverted
to myofibroblast phenotypes.
Cell-mediated enzymatic degradation can be achieved through the incorporation
of protease-sensitive linkers such as matrix metalloprotease (MMP) or collagenase-
sensitive linkers. West and Hubbell demonstrated this by fabricating a collagenase or
7plasmin-sensitive copolymer through photopolymerization of acrylated PEG-peptide
macromers. The APGL peptide and VRN peptides rendered the macromers labile to
collagenase and plasmin, respectively [45]. Further, Chen et al. established a dextran
methacrylate hydrogel crosslinked with MMP sensitive bis-cysteine containing pep-
tides [46]. Permitting cell-mediated degradation led to single-cell migration and the
strand-like invasion of endothelial cells typical of angiogenesis.
User-defined matrix softening can be achieved through the incorporation of pho-
toresponsive linkers. For example, Anseth and colleagues utilized nitrobenzyl ether
crosslinker to establish a photodegradable hydrogel permitting on-demand matrix
softening [37]. Rapid (5 minutes) and stepwise degradation could be achieved through
constant and pulsed UV exposure. This platform also permitted patterning of mi-
croscopic and macroscopic structures to study cell migration. In particular, local gel
erosion led to increased spreading of fibrosarcoma cells.
1.2.3 Reversible Matrix Stiffening
In addition to matrix stiffening or softening alone, techniques to reversibly stiffen
or soften hydrogels are increasingly being developed [39–42]. Anseth et al. utilized
light-mediated azobenzene cis-trans isomerization to reversibly stiffen or soften hy-
drogels [39]. Moduli of the hydrogel was reversibly tuned (∼100-200 Pa) upon UV or
visible light exposure. In addition to the potential hazards of using UV light, a phys-
iologically relevant degree of stiffening was not achieved. Anseth and colleagues later
implemented a light-mediated reversibly stiffened hydrogel. Hydrogels were softened
using the above mentioned nitrobenzyl photocleavage and stiffened using radical poly-
merization of methacrylate functional groups [40]. Alternatively, supramolecular host-
guest interactions could be employed for reversible stiffening/softening hydrogels [41].
This was achieved by alternate addition and removal of macromolecular adaman-
tane in cyclodextrin immobilized hydrogels. However, challenges to this approach
include limited diffusion of macromolecular adamantane, as well as limited spatial
8control of stiffening/softening. In another example, Cao et al. utilized Dronpa145N,
a fluorescent protein to permit reversible stiffening [42]. Cyan and violet light ex-
posure induced conformational switches between monomeric and tetrameric states of
Dronpa145N, respectively. By fabricating protein polymers containing Dronpa145N
either gel-sol (cyan) or sol-gel (violet) transitions could be achieved. However, the
protein-polymer fabrication process was laborious, and 2 hours of illumination was re-
quired for the phase transition. Azobenzene and -cyclodextrin guest-host interactions
have also been employed to fabricate reversibly stiffened HA-based hydrogels [47]. HA
was modified with either azobenzene or -cyclodextrin to permit photoreversible in-
teractions between each moiety. Upon 420 nm light exposure, guest-host interactions
were formed due to azobenzene favoring a cis isomer state. This lead to an initially
stiff matrix. Upon UV light (365 nm) exposure, a 60% reduction in modulus was
attained owing to trans isomerization of azobenzene that led to decreased guest-host
interactions. In addition, Wong and colleagues reports the use of an azobenzene pho-
toswitchable crosslinker that confers matrix stiffening in the presence of blue light
irradiation and matrix softening under UV light exposure [48]. MSCs seeded on stiff-
ened substrates exhibited increased spreading with greater substrate stiffening. A
potential challenge to this approach is the necessity for long term (1 hour) exposure
to UV light.
1.3 Enzyme-mediated Crosslinking and Secondary Modifications of Ma-
trix Properties
1.3.1 Enzymatic Crosslinking of Hydrogels
Biological reactions such as protein conformational changes and enzymatic reac-
tions have been increasingly utilized to fabricate or to modify cell-laden hydrogels
[49–53]. Table 1.1 summarizes current enzymatic techniques for hydrogel modifica-
tion. For example, Lutolf et al. prepared hyaluronic acid (HA) based hydrogels utiliz-
ing transglutaminase-mediated HA-Glutamine and PEG-Lysine ligation [54]. Trans-
9glutaminase catalyzes the isopeptide bond formation between the -amine of lysine
and the -carboxamide of glutamine. However, transglutaminase has limited substrate
specificity and calcium dependency. In another example, laccase, which catalyzes di-
phenol crosslinking, was utilized by Rocasalbas et al. to crosslink phenolic-conjugated
gelatin and chitosan [55]. However, the hydrogels were formed in approximately two
hours, rendering the system ineffectual for cell encapsulation. Martens and colleagues
performed a comparative study of horseradish peroxidase (HRP), hematin, laccase,
and tyrosinase to crosslink phenol-containing hydrogels [49]. HRP and hematin both
require hydrogen peroxide and reduced cell viability immediately after encapsulation.
On the other hand, laccase and tyrosinase resulted in higher cell viability and pro-
liferation but took approximately 2.5 hours to fully crosslink. Furthermore, rotation
of the samples was required to ensure a homogeneous distribution of cells. Phospho-
pantetheinyl transferase, which catalyzes the reaction between the phosphopanethein
prosthetic group of coenzyme A and a serine residue, was used by Lutolf and colleagues
to crosslink PEG based hydrogels [56]. The reaction is highly specific, and the protein
can be obtained in high expression yields. However, its magnesium-dependency is a
notable drawback.
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Table 1.1. Enzymatic crosslinking methods used for hydrogels.
Enzyme Advantages Disadvantages
Transglutaminase
• Efficient gelation
• Cytocompatible crosslinking
• Short half-life
• Limited substrate
specificity
Laccase
• Simple phenolic substrates
• Cytcompatible crosslinking
• Requires oxygen
• Inefficient gelation
Horseradish
Peroxidase
• Efficient gelation
• Simple phenolic substrates
• Requires hydrogen
peroxide
Tyrosinase
• Simple phenolic substrates
• Cytocompatible crosslinking
• Requires oxygen
• Inefficient gelation
Phosphopantetheinyl
transferase
• High diffusivity (MW: 26 kDa)
• Substrate specificity
• Requires coenzyme A
and magnesium
• Inefficient gelation
Sortase A
• High diffusivity (MW: 18 kDa)
• Substrate specificity
• Reversibility
• Hydrolytically degradable
crosslinks
1.3.2 Enzyme-responsive Hydrogels
Enzyme-responsive polymers are being developed to confer matrix stiffening, soft-
ening, ligand removal, and ligand exchange. Ayyub and Kofinas utilized this con-
cept to develop enzyme inducible stiffened nanoparticle-hydrogel composites [57].
Chymotrypsin-sensitive peptide, CY↓KC (arrow indicates enzyme cleavage site), and
silica nanoparticles were incorporated into PEG-based hydrogels. Upon chymotrypsin-
mediated cleavage of the peptide, adsorption and physical crosslinking the nanopar-
ticles could occur leading to increased stiffening the hydrogels. Cell-mediated enzy-
matic removal of ligands has been demonstrated by conjugating bioactive moieties to
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protease-sensitive pendent molecules [58,59]. This concept was demonstrated by Sali-
nas and Anseth who designed a protease cleavable RGD tether [58]. In chondrogenic
culturing conditions, MSCs secreted proteases that led to the cleavage and release
of RGD. Thiol-acrylate hydrogels were fabricated with pendent MMP-13-sensitive
RGD-containing peptides. Increased MMP-13 secretion was observed within 7 days
of hMSC chondrogenesis, which led to cleavage and liberation of RGD motif. This led
to enhanced chondrogenic phenotypes, as indicated by increased expression of type 2
collagen.
1.3.3 Mushroom Tyrosinase-mediated Dityrosine Formation
MT, also known as polyphenol oxidase, can be used to modify hydrogel properties
owing to its catalytic activity in converting mono-phenolic residues into dihydrox-
yphenylalanine (DOPA) dimers [60] (Fig. 1.2).
Fig. 1.2. MT-mediated dityrosine formation. MT catalyzes the oxidation of pendent
tyrosine residues into dihydroxyphenylalanine (DOPA), DOPA quinone, and a
DOPA dimer.
This enzymatic reaction has been used to irreversibly crosslink synthetic PEG-
peptide hydrogels and natural gelatin-HA hydrogels. [34,61,62]. Using MT-triggered
crosslinking, Liu et al. has recently demonstrated that hyaluronic acid and dynamic
stiffening of gelatin-based hydrogels synergistically enhanced migratory phenotypes
in PDAC cell types [62]. In particular, hydrogels consisting of thiolated-HA and
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dually-functionalized gelatin (with 4-hydroxyphenyl acetate (HPA) and norbornene
(NB) groups) were initially crosslinked through thiol-norbornene photoclick chem-
istry. Upon MT incubation, the HPA groups were dimerized, leading to higher ma-
trix stiffness. In another example, MT was utilized to crosslink tyramine-conjugated
hyaluronic acid and gelatin hydrogels [63]. The hydrogels exhibited tissue-adhesive
properties, and the degradation kinetics were modulated by varying tyramine sub-
stitution and MT concentrations. While MT is useful in secondary crosslinking of
hydrogels, its utility is limited by the available molecular oxygen, a co-factor for
the reaction. Furthermore, MT-mediated reaction leads to irreversible increase in gel
crosslinking, which precludes the use of this material system for studying the influence
of matrix softening on cell behaviors.
1.3.4 Sortase A Peptide Ligation
Staphylococcus aureus SrtA is a low molecular weight (∼18 kDa) transpeptidase
with high substrate specificity [64]. Being a cysteine transpeptidase, SrtA covalently
ligates two short peptide sequences, Leu-Pro-X-Thr-Gly (where X is any amino acid
except proline) and an oligoglycine, Gn where n is greater than one (Fig. 1.3).
Fig. 1.3. Schematic of SrtA-mediated transpeptidation. Note that the final product,
LPRTGGGG, can undergo further transpeptidation reactions.
13
Mechanistically, SrtA cleaves the amide bond between the Thr and Gly residues
of LPXTG and forms a thioether intermediate that is resolved by a nucleophilic
oligoglycine. Notably, this product is itself a substrate for future SrtA-mediated
transpeptidation reactions, thus permitting reversible reactivity. SrtA has been used
in a multitude of protein engineering applications including N- and C-terminal protein
labeling [64], antibody modification [65, 66], and peptide cyclization [67]. Griffith
and colleagues reported the first use of SrtA to perform primary crosslinking and
modification of hydrogels [52, 68, 69]. PEG-peptide hydrogels were crosslinked using
SrtA substrate functionalized PEG hydrogels. Additionally, epidermal growth factor
(EGF) was modified with SrtA substrate NH2-GGG (GGG-EGF). The growth factor
was immobilized onto PEG hydrogels through incubation with SrtA. To remove the
immobilized growth factor, SrtA with soluble glycine (GGG) was added.
1.3.5 Strategies to Immobilize Enzyme-responsive Substrates into Hy-
drogels
Biorthogonal reactions (i.e., cytocompatible chemistries with high selectivity and
rapid kinetics [70]) are often employed to incorporate enzyme-sensitive substrates in
hydrogel networks. For example, thiol-ene photoclick chemistry is widely utilized
orthogonal chemistry in hydrogel fabrication and modification [71–74]. The mech-
anism by which thiol and ene moieties are crosslinked occurs under light exposure.
Thiyl radicals, are generated by extraction of a hydrogen atom from the thiol group,
form covalent bonds with an ene functional group to form a step growth network
(Fig 1.4A). Due to the simplicity of enzyme substrates (e.g., GGG and LPXTG
for SrtA and Y for MT), peptides can be designed and covalently immobilized to
macromers using thiol-norbornene photoclick chemistry (Fig. 1.4B). This is advan-
tageous due to its efficiency (∼30 min reaction time) and orthogonality between the
cysteine-containing peptide and norbornene functionalized macromer. The peptide-
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functionalized macromers can be subsequently crosslinked or modified using the above
mentioned predictable and efficient enzymatic reactions.
Fig. 1.4. Schematic representation of (A) thiol-ene step growth polymerization and
(B) thiol-ene-mediated conjugation of pendent peptides to 8-arm PEGNB.
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2. OBJECTIVES
2.1 Overview
Enzymatic reactions can overcome some of the challenges associated with syn-
thetic approaches in crosslinking and modification of hydrogels. While SrtA peptide
ligation has been used in hydrogel-based applications, the mechanical properties and
gelation kinetics are not well characterized. In addition, its use in conjunction with
additional enzymatic reactions such as MT-mediated dityrosine formation was not
reported prior to this thesis work. Furthermore, the inherent reversibility of SrtA
peptide ligation is advantageous for fabricating hydrogels with reversibly tunable
properties. To demonstrate the utility of orthogonal enzymatic reactions to design
hydrogels with temporally tunable properties, two objectives are proposed:
2.2 Objective 1: Establish Enzyme-mediated Reversible Crosslinking of
Hydrogels
The first objective of this thesis was to use SrtA-mediated peptide ligation for
crosslinking PEG-based hydrogels, followed by using MT-mediated dityrosine forma-
tion to tune matrix stiffness. By adjusting SrtA and substrate concentration, the
rate of gelation and initial modulus was systematically altered. The enzymatic and
hydrolytic degradation of SrtA-mediated crosslinked hydrogels in the presence of vari-
able enzyme concentrations and soluble oligoglycine substrate were investigated. In
addition, the cytocompatibility of SrtA-mediated crosslinking was established with
MIN6, a mouse insulinoma cell line, and COLO-357 cells, a PDAC cell line. Ma-
trix stiffening could be tuned by adjusting total tyrosine content and MT incubation
time. In addition, the reversibility of SrtA-mediated transpeptidation was utilized to
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fabricate hydrogels with reversible matrix stiffening. The degree of matrix stiffening
was adjusted by varying SrtA concentration and incubation time, and softening was
adjusted by varying enzyme as well as soluble glycine concentration. The process was
also shown to be reversible for two cycles through alternate addition of Srt and SrtA
with soluble glycine.
2.3 Objective 2: Investigate the Role of Matrix Stiffening on Cancer Cell
Survival, Spheroid Formation, and Chemoresistance
After establishing a PEG-based hydrogel platform that permits tunable enzy-
matic crosslinking and on-demand stiffening/softening, the second objective was to
evaluate the role of matrix stiffening on cancer cell survival and spheroid formation.
Cell viability and spheroid diameter were monitored with and without MT-mediated
hydrogel stiffening. The reversibility of SrtA peptide ligation was used to control
spheroid formation of COLO-357 cells. Live/dead staining was used to determine
cell viability and spheroid diameters. Lastly, COLO-357 cells in stiffened hydrogels
were treated with gemcitabine to ascertain the effect of matrix stiffening on drug
responsiveness in the cells. Metabolic activity and viability were monitored by Ala-
marBlue and live/dead staining, and cancer stem cell marker expression was analyzed
by PCR. The results in this study establish the biological relevancy of our platform
to investigate cancer cell survival in the presence of matrix stiffening.
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3. MATERIALS AND METHODS
3.1 Materials
Eight-arm PEG-OH (20 kDa) was acquired from JenKem Technology, USA. 5-
Norbornene-2-carboxylic acid, N,N-dicyclohexylcarbodiimide (DCC), 4-(dimethylami-
no)pyridine (DMAP), dimethyl phenylphosphonite, 2,4,6-trimethylbenzoyl chloride,
2-butanone, lithium bromide, and diethyl ether were obtained from Sigma-Aldrich.
Fmoc-protected amino acids N,N,N,N -tetramethyl-O-(1H -benzotriazol-1-yl)uronium
hexafluorphosphate (HBTU), and hydroxybenzotriazole (HOBt) were purchased from
ChemPep or Anaspec. BL21 E. Coli was purchased from New England Biolabs.
Kanamycin sulfate was obtained from IBI Scientific. Lysogeny broth, Lennox formula-
tion, agar and broth were obtained from DOT Scientific. Isopropyl -D-1-thogalactopyr-
anoside (IPTG) was obtained from Sigma Aldrich. Sensolyte c© 520 Sortase A activity
assay kit was obtained from Anaspec. Dulbeccos Phosphate Buffered Saline (DPBS),
Hanks Balanced Salt Solution (HBSS), fetal bovine serum (FBS), 100X antibiot-
icantimycotic (anti-2), and Dulbeccos modified eagle medium (DMEM) were pur-
chased from Hyclone. Gemcitabine was obtained from TSZ CHEM. Mammalian cell
Live/Dead staining kit was obtained from Life Technologies Corp. All other chemicals
were obtained from Fisher Scientific unless otherwise noted.
3.2 PEG Macromer, Peptides, and Photoinitiator Syntheses
Eight-arm PEG-norbornene (PEG8NB, 20 kDa) was synthesized following pre-
vious protocols with minor modifications [75]. In anhydrous DCM, 5-norbornene-2-
carboxylic acid (5-fold molar excess to hydroxyl groups on PEG, 5X) was reacted with
DCC (2.5X) for 1 hour. The resulting norbornene anhydride was filtered to remove
18
by-product urea and added dropwise from an addition funnel to a two-necked round
bottom flask containing 8-arm PEG-OH, DMAP (0.5X), and pyridine (0.5X) under
nitrogen. The flask was covered and the reaction was allowed to proceed overnight.
The process was repeated to improve norbornene functionalization of the PEG.The
PEG8NB product was precipitated in cold diethyl ether and dried in vacuo. The dried
product was redissolved in and dialyzed against double distilled H2O (ddH2O) for 3
days at room temperature (MWCO: 6000-8000 kDa), followed by lyophilization.1H
NMR (Bruker Advance 500) was used to confirm the degree of PEG functionalization
(>90%, Appendix A).
All peptides (Table 3.1) were synthesized with standard Fmoc coupling chemistry
in an automated, microwave-assisted peptide synthesizer (Liberty 1, CEM). The crude
products were cleaved from resin in 95% trifluoroacetic acid (TFA), 2.5% ddH2O, 2.5%
Trisisopropylsilane (TIS), and 5% (w/v) phenol) for 3 hours at room temperature.
The crude peptides were precipitated in cold ethyl ether and dried in vacuo. The dried
peptides were purified using HPLC (Flexar system, Perkin Elmer) and confirmed by
mass spectrometry (QTOF, Agilent Technologies). Ellmans assay (PIERCE) was
used to quantify peptide stock concentrations by quantifying the concentration of the
sulfhydryl group.
Table 3.1. Peptides used in enzymatic crosslinking of hydrogels.
Peptide
Primary Crosslinking
Chemistry
Secondary Crosslinking
Chemistry
NH2-GGGGC-CONH2
SrtA-mediated peptide
ligation
N/A
NH2-CYLPRTG-CONH2
SrtA-mediated peptide
ligation
MT-mediated dityrosine
formation
NH2-GGG-CKGGGKC-
LPRTG-CONH2
Thiol-ene photoclick
chemistry
SrtA-mediated peptide
ligation
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Photoinitiator lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) was syn-
thesized as described elsewhere [76]. Briefly, to a round bottom flask containing
dimethylphenylphosphinate, an equal amount of 2,4,6-trimethylbenzoyl chloride was
added under nitrogen. The reaction proceeded overnight. 4-molar excess of lithium
bromide in 2-butanone was added to the reaction mixture that was heated to 50 oC.
After 10 minutes, solid LAP was observed. The reaction mixture was cooled to room
temperature and maintained for 4 hours. The mixture was filtered through a fritted
funnel and washed with 2-butanone 3 times and cold ethyl ether to remove unreacted
lithium bromide. 1H NMR was used to confirm product formation.
3.3 PEG-peptide Conjugate Synthesis
PEG-peptide conjugates were prepared through thiol-norbornene photoclick chem-
istry by reacting purified cysteine-bearing peptides with PEG8NB. Peptide concentra-
tions were determined through Ellmans assay. For conjugation to PEG8NB, desired
amount of peptides (1.5-fold excess to norbornene groups) were added to a flask con-
taining PEG8NB and photoinitator LAP (5 mM). The reaction mixture was exposed
to light (Omnicure s1000, 365 nm, 40 mW/cm2) for 30 minutes. To improve the
conjugation efficiency, an additional 5 mM of LAP was added after 15 minutes. The
products were dialyzed against ddH2O for 2 days to remove excess peptides and LAP,
followed by lyophilization to obtain purified PEG-peptide conjugates. The conjugates
were stored at -20 oC prior to use.
3.4 Heptamutant Sortase A Expression and Purification
Calcium-independent, heptamutant SrtA (P94R, E105K, E108Q, D160N, D165A,
K190E, K196T) was expressed as described elsewhere [77]. Competent BL21 E. Coli
were transformed with pet30b-7M SrtA plasmid (a gift form Hidde Ploegh. Addgene
plasmid # 51141) and grown on an LB-agar selection plate containing kanamycin (30
µg/mL). Individual colonies were picked and inoculated (220 rpm at 37 oC overnight
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in 10 mL of LB media supplemented with kanamycin (30 µg/mL) The cultures were
diluted 100-fold in LB media supplemented with kanamycin and shaken on an orbital
shaker (220 rpm at 37 oC) until the optical density at 600 nm (OD600) reached 0.4-0.6.
SrtA expression was induced by adding IPTG (400 µM). Following 3 hours (220 rpm at
37 oC) of incubation, cells were isolated by centrifugation (8000 rpm, 15 minutes) and
stored at -80 oC until lysis. Cell lysis was achieved by resuspending and incubating
cells in lysis buffer (20 mM Tris, 50 mM NaCl, 0.2 mg/mL lysozyme, 1 mM PMSF,
1x Halt EDTA-free protease inhibitor Cocktail, and DNase I) for 30 minutes at 4
oC, followed by sonication 2 cycles of 3 minutes with 30% duty cycle, 20% amplitude
followed by a 3-minute cool-down period). Lysates were cleared by centrifugation
(10,000g, 20 minutes, 4 oC) and purified with His60 Ni Superflow resin and columns
per manufacturers protocol. The purity of eluted fractions was analyzed by SDS-
PAGE and Western blotting with anti-6X His tag antibody. Pure fractions were
combined and concentrated to ∼60 mg/mL with Ultra-15 Centrifugal Filter Units
(Amicon). Buffer exchanged was performed against DPBS with Zeba Spin desalting
columns (MWCO: 7 kDa, Thermo Fisher Scientific). Concentrated SrtA aliquots
were sterile filtered and stored at -80 oC prior to use. Stock concentrations were
obtained by Ellmans assay by quantifying the free sufhydryl on SrtA. Heptamutant
SrtA activity was verified against the wild type protein using Sensolyte c© 520 Sortase
A activity assay kit per the manufacturer’s protocol.
3.5 Sortase A-mediated Hydrogel Crosslinking and Characterization
Hydrogels were fabricated by crosslinking PEG-YLPRTG and NH2-GGGG-PEG
with specified concentrations of SrtA as indicated. Both PEG-peptide macromers
were dissolved in PBS and combined. For rheological analysis, SrtA was added to
PEG-peptide mixtures and injected between two glass slides separated by 1 mm
Teflon spacers. Gelation was performed for 10 minutes unless otherwise specified.
Prior to rheometric measurement, hydrogels were incubated in PBS at 37 oC for 16
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hours. Oscillatory rheometry in strain-sweep mode (CVO 100, Bohlin) was employed
to measure the hydrogel storage and loss moduli (G’ and G”). The reported storage
modulus values were averaged from the linear region of the modulus-strain curves. In
situ rheometry was performed in time sweep (0.5% strain, 1 Hz frequency, and 90 µm
gap size at 25 oC) to obtain gelation kinetics. Immediately after adding SrtA, the
precursor was injected between the rheometer platform and parallel plate geometry
with the edge sealed with mineral oil to prevent evaporation.
To determine the swelling ratio and gel fraction, hydrogels were fabricated using
the above-mentioned procedure and immediately dried in vacuo. After one day the
dried hydrogel weight was measured and denoted as Wdry,1. The dried gels were then
incubated in ddH2O at 37
oC to remove sol fraction followed by a second 24 hour
drying process to obtain dry weight two (Wdry,2). Gel fraction was calculated using
the following equation:
Gel Fr. = Wdry,2/Wdry,1
To characterize swelling ratio, the hydrogels were swollen for 1 day in PBS at 37
oC and weighed to obtain the swollen weight (Wswollen). The mass swelling ratio (Q)
was defined as:
Q = Wswollen/Wdry,2
3.6 Sortase A-mediated Hydrogel Degradation and Characterization
After SrtA-mediated polymerization of hydrogels, the initial mass (W0) of the
hydrogels was measured. The gels were then placed in wells containing varied concen-
trations of SrtA with soluble glycinamide (48 mM, 3-fold excess to crosslinker concen-
tration) for transpeptidation-mediated degradation or SrtA only for SrtA-mediated
hydrolytic degradation. Gels were removed from SrtA-containing solution at specified
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time points, blotted dry, weighed (Wt), and returned to solution. This process was
repeated until the gel was fully degraded. Results are presented as mass loss defined
as:
Mass loss (%) = 100*(Wt-W0)/W0
3.7 Sortase A-mediated Reversible Stiffening of Hydrogels
Hydrogels were fabricated using thiol-ene photopolymerization with macromer
PEG8NB, peptide GGG-CKGGGGKC-LPRTG (Rthiol:ene = 1), and photoinitiator
LAP (1 mM) by mixing components at desired concentrations and injecting the mix-
ture between glass slides separated by 1 mm Teflon spacers as described above. The
precursor solutions were subjected to 365 nm light (5 mW/cm2, 2 minutes) for gel
casting. To induce stiffening or softening, hydrogels were either incubated in buffer
containing SrtA or SrtA with soluble glycinamide, respectively. Moduli were mea-
sured prior to and after stiffening or softening. Due to the volumetric shrinkage or
swelling, the gap size was reduced from 750 µm to 500 µm for stiffening and increased
from 500 µm to 650 µm for softening.
3.8 Mushroom Tyrosinase-mediated Stiffening and Characterization
Hydrogels were fabricated with the gelation method described in Section 3.5 and
incubated for 16 hours prior to stiffening. To achieve stiffening, gels were placed in
wells containing 1 kU/mL MT. Using oscillatory rheometry in strain-sweep mode as
described above, moduli were measured prior to and after hydrogel incubation with
MT (1 kU/mL) at 37 oC. Due to volumetric shrinkage of the stiffened gels, the gap
size for RGGGG:LPRTG = 1, RGGGG:LPRTG = 3 were reduced from 525 µm to 475 µm
and 700 µm to 625 µm, respectively.
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3.9 MIN6 and COLO-357 Cell Culture
COLO-357 cells were maintained in high glucose DMEM containing 10% FBS
and 1X-antibioticantimycotic (Anti-2). MIN6 cells, a mouse insulinoma cell line,
were maintained in high glucose DMEM containing 10% FBS, and 1X-Anti-2 and 50
µM -mercaptoethanol. For both cell lines, media was refreshed every 2-3 days.
3.10 Sortase A-mediated encapsulation of MIN6, and Characterization
of Cell Viability and Morphology
Prior to encapsulation, MIN6 and COLO-357 cells were trypsinized, counted
(Countess c© II Automated Cell Counter, ThermoFisher), and resuspended in HBSS
or DPBS, respectively. The resuspended cells were mixed with sterile-filtered pre-
polymer containing PEG-YLPRTG and NH2-GGGG-PEG. SrtA was added to ini-
tiate gelation and the mixture was immediately injected into a 1 mL syringe mold.
Curing proceeded for 10 minutes prior to placing the gels in fresh media. Metabolic
activity was monitored with AlamarBlue reagent. In brief, COLO-357 and MIN6-
laden hydrogels were incubated with AlamarBlue working reagent (diluted 10-fold
with culture media) for 2.5 and 16 hours, respectively. Further, live/dead staining
and imaging was implemented to assess cell viability per manufacturers protocols.
Following washing to remove excess dye, stained cell-laden hydrogels were imaged by
confocal microscopy (Olympus Fluoview FV100 laser scanning microscope). Z-stack
images (100 µm thick with 10 µm slices) from one gel and at least three random fields
were captured for each condition.
3.11 In situ Mushroom Tyrosinase-mediated stiffening of COLO-357-laden
Hydrogels and Characterization of Cell Viability and Morphology
SrtA-mediated crosslinked cell-laden hydrogels were fabricated as described above.
The hydrogels were transferred to a 24-well plate containing media supplemented with
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1 kU/mL MT and incubated for 6 hours at 37 oC in 5% CO2 to induce stiffening.
The hydrogels were transferred to and maintained in a new well containing fresh
media. Live/dead staining and imaging was performed as described above and cell
morphology was analyzed using Nikon NIS-element software.
3.12 Sortase A-mediated reversible stiffening of COLO-357-laden Hydro-
gels and Characterization of Cell Viability
Cells were encapsulated using the procedure described in Section 3.9 with mod-
ification. Photoinitator LAP was added to the precursor solution with cells. The
mixture was injected into a syringe mold, and subjected to UV-light (365 nm, 5
mW/cm2, and 2 min.). After casting, the gels were transferred to a 24-well plate
containing fresh media. Cells were allowed to grow for 7 days prior to matrix stiffen-
ing by incubating the cell-laden hydrogels in media containing 50 µM of SrtA for 4
hours. On day 14, the hydrogels were subject to matrix softening through incubation
in media containing 50 µM of SrtA and 15 mM glycinamide (3-fold to SrtA substrate
concentration). Live/dead staining and imaging was implemented on day 1, 7, 14,
and 21 to qualitatively investigate cell viability. Spheroid diameters were measured
using Nikon NIS-element software.
3.13 Gemcitabine Resistance, Cell Viability, and Apoptosis Assays
Cells were encapsulated by thiol-ene photopolymerization using the methodology
described in Section 3.12. After 3 days of growth, hydrogels were treated with SrtA
(50 µM) for 4 hours to induce matrix stiffening. Four days post-stiffening the hydro-
gels were treated with 1 µM gemcitabine for 3 additional days. Metabolic activity and
morphology of the cells were assessed by AlamarBlue reagent and Live/dead staining,
respectively.
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3.14 RNA Extraction and Real-time PCR
RNA isolation was completed using Nucleospin RNA isolation kit (Clontech).
Briefly, 350 µL of lysis buffer was added to tubes containing cell-laden hydrogels. Sub-
sequently, the hydrogels were homogenized using QIAShredder Homogenizer columns
(Qiagen). Lysates were filtered, and RNA was precipitated through the addition of
70% ethanol and vigorous pipetting. Following desalting and wash steps, RNA was
eluted with DNase/RNase-free H2O and quantified by spectrophotometry (Nanodrop
2000, Thermo Scientific).
Complementary DNA (cDNA) was generated by using Prime-Script RT reagent
kit (Clontech) per the manufacturers protocol. Gene expression was analyzed by real
time quantitative PCR using SYBR Premix Ex Taq II Kit (Clontech). All components
(i.e., kit components, cDNA, and primers (Appendix B)) were mixed and transferred
to a PCR plate. Analysis was completed using the 7500 Fast Real-Time PCR machine
(Applied Biosystems), and results were analyzed using the 2−∆∆Ct methodology. For
all conditions, cycle count was standardized to GAPDH house-keeping gene (∆Ct)
and normalized to the control group (∆∆Ct).
3.15 Statistics
Statistical analyses were conducted using either a two-tailed t-test or a two-way
analysis of variance (ANOVA) and when permitted followed by a Bonferroni post-hoc
test to evaluate significance between experimental groups. A p value < 0.05 was
considered statistically significant. Single, double, and triple asterisks represent p <
0.05, 0.01, 0.001, respectively. All experiments were completed independently at least
three times and quantitative results are presented as mean ± SEM.
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4. RESULTS AND DISCUSSION
4.1 Validation of Heptamutant SrtA Enzymatic Activity and Calcium
Independence
Heptamutant SrtA (i.e., SrtA7M) was utilized throughout this thesis due to its im-
proved stability and enhanced reactivity compared with the wild type SrtA (SrtAWT )
[78]. The mutations of P94R/D160N/D165A/K190E/K196T increase catalytic effi-
ciency (kcat/Km) by 140-fold [79], whereas mutations E105K/E108A confer the re-
action calcium-independent due to the stabilization of the critical calcium-binding
β6/β7 loop [78]. The expression and purification of SrtA7M was confirmed by SDS-
PAGE (Fig. 4.1A) and western blotting with antibody against hexahistadine tag
(Fig. 4.1B).
Fig. 4.1. (A) SDS-PAGE and (B) Western Blot of SrtA (∼18 kDa) expressed in
BL21 E Coli.
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The catalytic activity of SrtA7M was verified by comparing against the commer-
cially available SrtAWT in the absence or presence of Ca
2+ (Figs. 4.2A and B, respec-
tively). While both wildtype and heptamutant SrtA were active in buffer containing
Ca2+, only SrtA7M was active in a Ca
2+-deprived environment. Taken together, these
results agree with the literature regarding the Ca2+-independent enzymatic activity
of SrtA7M [78, 80].
Fig. 4.2. Wild type SrtA (SrtAWT ) and Heptamutant SrtA (SrtA7M) activity in
Tris-HCl (pH=8.0) buffer with 50 nM SrtA, 2 µM 5-FAM/QXL FRET peptide
substrate, and 2 mM oligo-glycine peptide (i.e., GGGGC) in the presence (A) or
absence (B) of 10 mM CaCl2. SrtA inducted substrate cleavage was detected by the
fluorescence of the 5-FAM substrate (Ex/Em = 490/520). RFU: relative
fluorescence units.
4.2 Gelation Kinetics of SrtA-mediated Crosslinking of PEG-peptide Hy-
drogels
To render hydrogels susceptible to SrtA-mediated crosslinking and MT-mediated
secondary stiffening (Figs. 4.3 and 4.14), two sets of peptide substrates (i.e., CYLPRTG-
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amide and NH2-GGGGC-amide) were separately conjugated to PEG8NB macromers.
Peptides bearing cysteine and tyrosine residues permit thiol-norbornene coupling of
the PEG-peptide conjugates and MT-mediated stiffening, respectively (Fig. 1.5B).
Fig. 4.3. Schematic of SrtA-mediated gelation. Peptides (YLPRTG and GGGG)
were tethered to PEG macromers using thiol-norbornene click chemistry. Gelation
was initiated after addition of SrtA.
Gelation kinetics at varied concentrations of SrtA (Fig. 4.3A) were determined by
in situ rheometry. At a stochiometric equivalence of GGGG:LPRTG (RGGGG:LPRTG
= 1) and a total PEG-peptide concentration of 2 wt%, higher concentrations of SrtA
accelerated the speed of gelation as indicated by a rapid increase in shear modulus
(G). Specifically, the gel point (the time in which the storage modulus crosses over
the viscous modulus) for 150 µM, 300 µM, and 600 µM of SrtA were 302 s, 148 s,
and 81 s, respectively). This was expected as higher enzyme concentrations increase
the maximum velocity (Vmax) of the transpeptidation reaction.
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Fig. 4.4. (A) In situ rheometry of PEG-peptide (2 wt%, RGGGG:LPRTG = 1)
hydrogel crosslinking. G” omitted for clarity. (B) Gel points were calculated by
determining the initial time point at which G′ was greater than G”.
While gelation kinetics could be captured by in situ rheometry at higher concentra-
tions of SrtA, a conventional tilt test can ascertain longer gelation times at lower en-
zyme concentrations (Fig. 4.5). Solutions of 6 wt% PEG-peptide (RGGGG:LPRTG=2)
were incubated at 25 oC with varied concentrations of SrtA. Like results shown in
Figure 4.4, the gelation speed scaled with SrtA concentrations. Remarkably, the gela-
tion time could be adjusted from a range of ∼10 minutes to ∼1.5 hours by simply
adjusting the enzyme concentration without modifying other formulation parameters.
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Fig. 4.5. Tilt test to track long-term gelation of PEG-peptide hydrogels. Eosin-Y (1
mM, red dye) was added for image clarity.
4.3 Effect of SrtA-mediated Crosslinking on the Modulus of PEG-peptide
Hydrogels
Rheometry can be implemented to investigate the effect of SrtA concentration on
the elastic modulus at a fixed total concentration of PEG-peptide (3 wt%, RGGGG:LPRTG=1).
The gelation continued at 37 oC for 10 minutes prior to placement in PBS buffer for
equilibration (16 hrs.). At 10 minutes of gelation, concentration of SrtA did not
significantly affect the final gel moduli (Fig. 4.6A). Furthermore, 300 µM of SrtA
and 10 minutes of gelation was sufficient to complete gelation as extending the gela-
tion time to 16 hours only moderately but not statistically significantly increased
the gel moduli (∼5,700, ∼6,350, ∼6,500 Pa for 10, 60, and 960 minutes of gelation,
respectively. Fig. 4.6B). Moreover, tuning the total PEG-peptide concentration at
a fixed RGGGG:LPRTG=1 increased the moduli of hydrogels. Specifically, gel moduli
were ∼2,700 Pa, ∼6,000, and ∼10,000 Pa for 2%, 3%, and 4% PEG macromer, re-
spectively (Fig. 4.6C). These results suggested that it was possible to reach complete
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gelation within 10 minutes using SrtA at as low as 150 µM. For the remainder of this
study, 300 µM of SrtA was utilized for its gel point suitable for pipetting, solution
mixing, and cell encapsulation. Together these results demonstrated exquisite control
of matrix stiffness by adjusting gelation parameters such as enzyme concentration,
gelation time, and total macromer concentration. Furthermore, the final crosslinking
density of the hydrogels could be decoupled from gelation kinetics by simply varying
the SrtA concentration.
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Fig. 4.6. (A) Effect of SrtA concentration on the modulus of PEG-peptide hydrogels
(3 wt%, RGGGG:LPRTG = 1). (B) Effect of gelation time on the modulus of
PEG-peptide hydrogels (3 wt%, RGGGG:LPRTG=1, 300 µM SrtA). (C) Effect of
PEG-peptide concentration on the modulus of hydrogels (10 min gelation, 300 µM
SrtA).
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4.4 Effect of Substrate Ratio RGGGG:LPRTG on SrtA-mediated Hydrogel
Crosslinking
The inherent reversibility of SrtA transpeptidation is a notable drawback of SrtA-
mediated primary hydrogel crosslinking. This reversibility stems from the fact that
cleaved glycine-containing by-products also serve as substrates for additional transpep-
tidation [81]. On the other hand, in solution with low glycine content, the thioacyl
LPXT-SrtA intermediate can be hydrolyzed, rendering the product (i.e., LPXT-OH)
unreactive for future transpeptidation reactions [81]. To investigate these phenom-
ena and their effect on SrtA-mediated crosslinking, hydrogels were fabricated with
different ratios of PEG-LPRTG and NH2-GGGG-PEG substrates as per Table 4.1.
Table 4.1. Formulations of PEG-peptide hydrogels used in Figures 4.7 and 4.16.
RGGGG:LPRTG
PEG-
YLPRTG
(wt%)
GGGG-
PEG
(wt%)
Total PEG
(wt%)
[YLPRTG]
(mM)
[GGGG]
(mM)
1/3 1.5 0.5 2 6 2
1 1.5 1.5 3 6 6
3 1.5 4.5 6 6 18
3 2.5 7.5 10 10 30
The hydrogels containing an equimolar ratio of substrates exhibited higher moduli
(G′: ∼10,000 Pa) than the gels fabricated at RGGGG:LPRTG=1/3 (G′: ∼1000 Pa) and
3 (G: ∼1500 Pa Fig. 4.7A). This suggests that an equimolar ratio of substrate yielded
a hydrogel network with less structural defects compared to hydrogels with off-ratio
substrate concentrations. Hydrogels containing higher amounts of NH2-GGGG-PEG
substrate exhibited significantly higher gel fraction (0.4, 0.7, and 0.8 for RGGGG:LPRTG
= 1/3, 1, and 3, respectively Fig. 4.7B). Hydrogels fabricated with RGGGG:LPRTG =
1/3 exhibited lower gel fraction potentially due to a loss of unreacted PEG-LPRTG.
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We also speculate that an excess of unreacted NH2-GGGG-PEG arms lead to network
defects; however, the additional oligoglycine substrate drove the reaction towards
transpeptidation, hence leading to increased gel fraction (Fig. 4.7B).
Fig. 4.7. (A) Effect of RGGGG:LPRTG on the hydrogel modulus. Gap sizes utilized for
RGGGG:LPRTG = 1/3, RGGGG:LPRTG = 1, and RGGGG:LPRTG = 3 were 475 µm, 525
µm, and 700 µm, respectively. (B) Effect of RGGGG:LPRTG on the gel fraction.
Notably, the effect of varying total PEG-peptide conc. at a fixed RGGGG:LPRTG
= 3 had significant effect on the elastic modulus of the hydrogels. In particular,
hydrogels fabricated at 6 wt% and 10 wt% of total PEG-peptide exhibited similar
moduli (∼1,000 Pa) while the modulus of 8 wt% hydrogels was significantly higher
(∼2,000 Pa, Fig. 4.8A). It was likely that at constant Vmax for both conditions,
additional time was necessary for SrtA to achieve complete gelation for the 10 wt%
hydrogels. Further, at high concentrations, the macromer components may be func-
tioning as crowding agents leading to enzyme aggregation and inactivity. This was
observed through the formation of a white precipitate in the presence of increasing
PEG-peptide concentration. This phenomenon further extends the time required for
complete gelation.
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Fig. 4.8. Effect of total PEG-peptide concentration on modulus at RGGGG:LPRTG =
3 (300 µM SrtA; 10 minute gelation time).
4.5 Degradability of SrtA-Crosslinked Hydrogels
The reversibility of the SrtA-induced transpeptidation can be utilized to erode
PEG-peptide hydrogels. Specifically, incubating the hydrogels with additional SrtA
and soluble glycine substrate leads to breakage of the LPRTG linker (i.e., transpep-
tidation mediated degradation. Fig. 4.9A). Even in the absence of glycine substrate,
the LPRT-SrtA thiolether intermediate would gradually resolve, leading to hydrolytic
cleavage of the peptide bond (Fig. 4.9B) and eventually hydrogel degradation. Both
mechanisms can be used to control degradation of hydrogels (i.e., bulk degradation
and surface erosion). Degradation can also be tuned without altering macromer and
peptide concentrations. The degradation mechanisms were systemically studied due
to their implications in drug delivery and tissue engineering applications.
36
Fig. 4.9. Schematic of SrtA-mediated (A) transpeptidation and (B) hydrolytic
degradation of PEG-peptide hydrogels.
To assess the effect of SrtA and a soluble, glycine-containing substrate on the
transpeptidation-mediated degradation, hydrogels (6 wt%, RGGGG:LPRTG=2) were
fabricated as described above, washed extensively to remove residual SrtA, and in-
cubated in buffer containing varying concentrations of SrtA and glycinamide (Fig.
4.10). As expected, degradation occurred in the presence of SrtA and glycinamide.
This was evident by the initial swelling (i.e. negative loss of mass) of the hydrogel
prior to the rapid decrease in mass. The enzyme treatment loosened the hydrogel
network permitting initial water uptake and hydrogel swelling. For 10 µM, 25 µM,
and 50 µM of SrtA, the gels reached complete degradation at approximately 9, 7,
and 5 hours, respectively (Fig 4.10A). Further gels in the non-treated control group
did not degrade. Additionally, the oliglycine concentration significantly affected the
degradation rate. Hydrogels were treated with 50 M of SrtA and 16 mM and 48 mM
of glycinamide (i.e., 1- and 3-fold to the glycine content in the hydrogels). As shown
in Figure 4.10B, full degradation was achieved in 5 hours for a 3-fold concentration
of soluble glycinamide. At a stochiometric ratio of soluble glycinamide to tethered
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GGGG, the hydrogels degraded in 7 hours, suggesting higher concentrations of soluble
substrate are required for faster degradation.
Fig. 4.10. Effect of (A) SrtA conc. and (B) NH2-Gly-CONH2 on SrtA mediated
transpeptidation degradation of hydrogels (6 wt%, RGGGG:LPRTG=2).
Compared with transpeptidation degradation, SrtA-mediated hydrolytic degra-
dation (i.e., without soluble glycinamide as nucleophile) occurred much slower and
appeared to proceed by way of surface erosion (Fig. 4.11). The gels degraded in
∼50 and ∼58 hours for 25 µM and 50 µM of SrtA, respectively. Similar to gelation
kinetics, the degradation rates can be tuned in a range of hours up to multiple days.
Further, the degradation rate can be slowed or stopped by washing the hydrogels
to remove SrtA. This can be exploited in the future for investigating cell behav-
iors in a gradually degrading microenvironment. As opposed to other protease (e.g.,
MMPs) degradation mechanisms, SrtA transpeptidation is highly specific and does
not interfere with cell-mediated protease activity. In addition, the selectivity of SrtA
transpeptidation allows for degradation without affecting large ECM proteins (e.g.,
collagen). These proteins can be later assayed for functional characterization of cell
response and protein secretion.
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Fig. 4.11. Effect of SrtA concentration on SrtA-mediated hydrolytic degradation of
PEG-peptide hydrogels (6 wt%, RGGGG:LPRTG = 2).
4.6 Cytocompatibility of SrtA-crosslinked Hydrogels
In situ encapsulation of mouse insulinoma cell line MIN6 and pancreatic cancer
cell line COLO-357 were utilized to demonstrate the cytocompatibility of the SrtA-
mediated gel crosslinking (Figs. 4.12 and 4.13). COLO-357 was used as a model cell
line for spheroid formation in the presence of dynamic stiffening, whereas MIN6 beta-
cells were encapsulated due to their vulnerability in bio-inert hydrogels at a relatively
low cell density [72,82]. From a previous report, it was suggested that approximately
0.3% of mammalian cell proteins contain the LPXTG substrate [69]. Therefore, SrtA-
mediated transpeptidation would have superior biocompatibility. Similar to reported
results [83], live/dead stained images showed that virtually all cells remained alive
following encapsulation (day 1). Furthermore, the encapsulated cells formed spheroids
by day 10 of in vitro culture in 3 wt% hydrogels (RGGGG:LPRTG=1) (Fig. 4.12A). The
encapsulated MIN6 cells exhibited increasing metabolic activity over the course of 7
days, suggesting the cells maintained their ability to proliferate even in the bio-inert
hydrogels (Fig. 12B).
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Fig. 4.12. Effect of SrtA-mediated crosslinking on the viability and metabolic
activity of MIN6 cells. (A) Representative z-stack images of live/dead stained cells
(2 x 106 cells/mL) encapsulated in PEG-peptide hydrogels, 3 wt%, RGGGG:LPRTG =
1). (B) The metabolic activity of encapsulated MIN6 cells (n = 3).
Similar to the encapsulation of MIN6 cells, nearly all COLO-357 cells remained
alive after encapsulation (day 1). The cells were metabolically active and formed
spheroids by day 7 (Fig. 4.13). There results were consistent with previous report
for this cell type cultured in 3D where metabolic activity peaked at around day 4,
followed by a steady decrease for the next 3 to 5 days [84]. The results here demon-
strated the cytocompatibility of SrtA-mediated crosslinking owing to the high sub-
strate specificity of the transpeptidation reaction. Although this thesis only explored
the encapsulation of COLO-357 and MIN6 cells, SrtA could potentially be used to
encapsulate a variety of mammalian cells, including stem cells.
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Fig. 4.13. Effect of SrtA-mediated crosslinking on the viability and metabolic
activity of COLO-357 cells. (A) Representative z-stack images of live/dead stained
cells (2 x 106 cells/mL) encapsulated in PEG-peptide hydrogels, 3 wt%,
RGGGG:LPRTG = 1). (B) The metabolic activity of encapsulated MIN6 cells (n = 3).
4.7 Mushroom Tyrosinase Stiffening of SrtA-crosslinked Hydrogels
As described by Liu et al., MT-stiffening is advantageous due to the simplicity
of the tyrosine substrates and the predictable reaction kinetics [34, 62]. To permit
MT-mediated stiffening in SrtA-crosslinked hydrogels, a single tyrosine residue was
incorporated in the PEG-peptide conjugate (i.e., PEG-Y-LPRTG). MT incubation
led to increased crosslinking density and matrix stiffness through dityrosine formation
(Fig. 4.14).
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Fig. 4.14. Schematic of MT-mediated dityrosine formation. Secondary crosslinking
was achieved upon incubation with MT.
After equilibration, the gels were placed in buffer containing MT (1 kU/mL).
For 3 and 6 hours of MT incubation, the moduli of hydrogels increased ∼1.25-fold
and ∼1.5-fold, respectively (Fig. 4.15A). In addition, dityrosine formation caused
yellowing/browning of the hydrogels, which was accompanied by volumetric shrinkage
of the gels. After 6 hours of MT incubation, the hydrogels underwent a 25% reduction
in size (Fig. 4.15B). These results indicated that on-demand matrix stiffening could
be achieved by simply incorporating tyrosine residues into the peptide linker of SrtA-
mediated crosslinked hydrogels. Additionally, the stiffening could be tuned by simply
adjusting MT incubation time.
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Fig. 4.15. (A) Effect of MT incubation time on the modulus of PEG-peptide
hydrogels (2 wt%, RGGGG:LPRTG = 1, MT = 1 kU/mL). (B) Representative images
of hydrogels incubated with MT for varying durations.
As demonstrated in Figures 4.7 and 4.8, substrate ratio plays a significant role in
determining the properties of SrtA-mediated crosslinked hydrogels. Hydrogels were
fabricated per table 4.1. For the 6 wt% and 10 wt% hydrogels, a fixed ratio of 3 was
used due to its desirable gel properties (low modulus and high gel fraction). While
both conditions exhibited similar initial shear moduli of ∼1 kPa, MT incubation
yielded higher moduli ∼3 kPa) in 10 wt% gels compared to 2 kPa for 6 wt% (Fig.
4.16). The higher degree of stiffening for 10 wt% hydrogels can be attributed to a
higher concentration of tyrosine residues (Table 4.1).
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Fig. 4.16. MT-mediated stiffening of PEG-peptide hydrogels (RGGGG:LPRTG = 3,
MT = 1 kU/mL).
4.8 Effect of MT Stiffening on the Generation of COLO-357 Spheroids
It is known that matrix stiffness plays a significant role on pancreatic cancer cell
growth and morphology [84]. High crosslinking density of cell-laden hydrogel could
cause significant strain on cells and inhibit their proliferation, whereas low crosslinking
density allows for hydrogel deformation by proliferating cell spheroids. Nonetheless,
the effect temporal changes in hydrogel crosslinking density on cell behaviors remains
challenging technologically.
To study the effect of dynamic matrix stiffening on COLO-357 spheroid morphol-
ogy, PEG-peptide hydrogels (10 wt%, RGGGG:LPRTG = 3) were fabricated for their
desirable initial modulus, gel fraction, and magnitude of stiffening (Figs. 4.7 and
4.16). It is important to note that the hydrogels were crosslinked without protease
sensitive linkers to study the sole effect of matrix stiffening without complication of
cell-mediated gel degradation. As shown in Figure 4.17, matrix stiffening inhibited
proliferation of COLO-357 cells, as indicated by the formation of cell spheroids with
smaller diameter. These results are consistent with previous reports on the effect of
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static matrix stiffness on COLO-357 spheroid sizes [84]. Both SrtA-mediated primary
and MT-mediated secondary crosslinking mechanisms did not induce cell damage as
no dead cells were observed in the live/dead staining images. While matrix stiffening
process was performed for 6 hours in this thesis work, it could be extended to mul-
tiple days using lower enzyme concentration or by performing a step-wise stiffening
procedure (i.e., incubate gels with MT in short periods of time periodically) to mimic
the timeframe of in vivo matrix stiffening.
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Fig. 4.17. (A) D1 and D10 live/dead images of COLO-357 cells (2 x 106 cells/mL)
with or without MT incubation (D1 stiffening, MT incubation time = 6 hrs.). (B)
Cell spheroid distribution with or without MT-mediated stiffening. Diameters were
quantified day 10 post-encapsulation. The diameters of the spheroids with and
without MT stiffening were 45.91 ± 0.67 µm (n = 594) and 39.48 ± 0.51 µm (n =
590), respectively. A two-tailed t-test was performed for statistical analysis (p <
0.01).
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4.9 SrtA-mediated Reversible Stiffening
In addition to degradation of PEG-peptide hydrogels, SrtA-mediated transpepti-
dation is a suitable approach for reversible matrix stiffening, and this approach has
not been reported in the literature. To prepare hydrogels with reversible stiffen-
ing/softening capability, hydrogel was first prepared by thiol-norbornene photoclick
chemistry with PEG8NB as a macromer and a unique linear peptide bearing bis-
cysteine residues and pendent SrtA substrates (i.e., GGG-CKGGGKC-LPRTG). This
approach is advantageous due to the orthogonality of the thiol and norbornene func-
tional groups and the quantitative immobilization of the SrtA peptide substrates (Fig.
4.18). Through SrtA-mediated transpeptidation, the pendent peptides are covalently
ligated resulting in increased crosslinking density and matrix stiffness. When needed,
the stiff hydrogel can be softened through incubation with SrtA and an excess of
soluble glycine substrate. In theory, this process could be repeatedly indefinitely if
SrtA-mediated hydrolytic degradation of the peptide bond is minimized by extensive
washing.
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Fig. 4.18. Schematic of SrtA-mediate reversible stiffening of PEG-peptide hydrogels.
Hydrogels were initially crosslinked via thiol-norbornene photoclick chemistry,
stiffened through incubation with SrtA, and softened through incubation with SrtA
and a N-terminal glycine-containing peptide.
To demonstrate the tunability of SrtA-mediated stiffening, PEG-peptide hydrogels
(2.5 wt%, Rthiol:ene=1) containing SrtA substrates were incubated with varying time
and concentrations of SrtA. (Fig. 4.19). As expected, the degree of stiffening increased
with incubation time as the enzyme diffused into the hydrogel (Fig. 4.19B). The initial
modulus (1 kPa) increased 1.75- to 2.5-fold in the presence of 25 µM of SrtA. However,
further stiffening at later time points was not observed, indicating that 3 hours was
sufficient for complete stiffening of the hydrogels. Additionally, the degree of stiffening
is dependent on SrtA concentration. In particular, 2- to 4-fold increases in matrix
stiffness were observed with SrtA concentrations from 10 to 50 µM and an incubation
time of 4 hours. Taken together, these results demonstrate that pathophysiologically
relevant degrees of stiffening [85, 86] can be achieved through SrtA-mediated peptide
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ligation. The magnitude and timing of stiffening could be tuned by adjusting enzyme
concentration and incubation time. Similar to the results in Section 4.2, gelation could
be theoretically extended by lowering the enzyme concentration without changing
other gel parameters.
Fig. 4.19. (A) Effect of SrtA incubation time on stiffening of PEG-peptide hydrogels
(2.5 wt%, Rthiol:ene = 1, 25 µM SrtA). (B) Effect of Srt conc. on stiffening of
PEG-peptide hydrogels (2.5 wt%, Rthiol:ene = 1, 4 hr incubation).
After initially stiffening the hydrogels, matrix softening can occur in the presence
of additional SrtA and soluble glycine substrate. As described in Figure 4.19, this
could be tuned by adjusting incubation time and enzyme concentration. However,
soluble glycine concentration could also influence the final modulus of the hydrogels
(Fig. 4.20). Stiffened moduli (G′Stiff , ∼3 kPa) were measured prior to incubation with
SrtA (25 µM) and concentration of glycinamide (0, 2.5, 5, and 15 mM corresponding
to 0, 0.5, 1, and 3-fold concentrations to crosslinker concentrations, respectively).
After 4 hours of incubation, the final moduli were measured. Softening ranged from
0.8- to 0.5-fold with increasing concentrations of glycinamide. Interestingly, at a
stoichiometric ratio of soluble and immobilized glycine (5 mM), minimal softening
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was attained. Further, nearly full softening was achieved at a 3-fold concentration of
soluble glycinamide. This is in line with literature suggesting high concentrations of
glycinamide are required to drive full transpeptidation [85–87].
As mentioned previously, SrtA-mediated hydrolysis presents challenges to this
strategy requiring extensive buffer replacement to remove residual SrtA and prevent
this from occurring. However, it may be utilized to achieve gradual softening of the
hydrogels (Fig. 4.20B). To demonstrate this, PEG-peptide hydrogels incubated with
SrtA (25 µM) for 16 hours achieved full softening without the necessity of glycine.
Again, softening could be extended by adjusting the enzyme concentration. However,
it is important to note that this process is irreversible as the product LPRT-OH is
generated rendering the peptide unreactive to the pendent glycine peptide.
Fig. 4.20. (A) Effect of Gly-CONH2 concentration on the softening of PEG-peptide
hydrogels (2.5 wt%, Rthiol:ene = 1, and 25 µM of SrtA). (B) SrtA-mediated
hydrolytic degradation of PEG-peptide hydrogels (2.5 wt%, Rthiol:ene=1, 16 hour
incubation time).
As shown in Figure 4.21, multiple cycles of stiffening and softening could be
achieved. SrtA was added initially to create secondary crosslinks between pendent
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LPRTG and GGGG. This covalent bond could be subsequently broken through the
addition of SrtA and soluble Gly-CONH2. The additional Gly-CONH2 (at 3-fold
concentration) competes with immobilized GGGG to regenerate the initial LPRTG
and GGGG substrates. Interestingly, a slight increase in modulus occurred after re-
moving the hydrogels from SrtA/glycinamide solution. This could be attributed to
re-stiffening of the hydrogels caused by residual SrtA (i.e., reforming peptide bond
between pendent LPRTG and GGG substrates). This dynamic crosslinking mecha-
nism offers a wide range of the degree of stiffening and flexibility in the timescale of
stiffening (i.e., hours to days).
Fig. 4.21. Cyclic stiffening and softening of PEG-peptide hydrogels (2.5 wt%).
Alternating 4-hour incubations with SrtA (25 µM) and SrtA with Gly-CONH2 (15
mM) correspond to stiffening and softening, respectively.
4.10 Effect of SrtA-mediated Reversible Stiffening on COLO-357 Spheroid
Formation.
To demonstrate the efficacy of this dynamically and enzymatically crosslinked hy-
drogel system as a platform for studying cell fate processes, COLO-357 cells were
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encapsulated in the SrtA-stiffened/softened hydrogels. In particular, cells were ini-
tially encapsulated in hydrogels with elastic moduli of 1 or 3 kPa. These moduli were
of biological relevance as 1 kPa and 3 kPa correspond to moduli of normal and desmo-
plastic pancreatic tissue, respectively [88, 89]. Cell laden hydrogels were fabricated
with 2.5 wt% and 3.5 wt% of PEG8NB, which yielded gels with initial moduli of ∼1
kPa (i.e., soft gels) and ∼3 kPa (i.e., stiff gel), respectively. The 2.5 wt% PEG8NB
hydrogels were treated with SrtA or SrtA with glycinamide to explore the effect of
dynamic stiffening and softening on cell fate. Both initial thiol-norbornene photopoly-
merization and subsequent stiffening and softening (Fig. 4.22A) were cytocompatible
as indicated by the high cell viability after each process (Fig. 4.22B). The diameters
of cell spheroids were significantly smaller in statically stiff hydrogels compared with
that in the soft gels. Spheroid growth was inhibited likely due to increasing crosslink-
ing leading that restricted cell proliferation. After allowing spheroid proliferation for
one week, the cell laden hydrogels were exposed to SrtA for 4 hours, which led to
gel stiffening. The spheroid growth rate was similar to spheroids grown in statically
stiff hydrogels (∼3% change in diameter). Upon softening by 4-hour incubation with
SrtA and glycinamide, spheroids growth resumed and matched more closely to the
growth profile of cell spheroids grown in statically soft hydrogels (∼15% change in
diameter). This is likely due to the loosening of the hydrogel network permitting cell
proliferation.
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Fig. 4.22. (A) Timeline of reversible stiffening of cell laden hydrogels. Cells were
allowed to grow in soft hydrogels prior to stiffening on day 7. Stiffened cell laden
hydrogels were subsequently softened on day 14 and imaged on days 1, 7, 14, and
21. (B) Representative confocal images of encapsulated COLO-357 cells in statically
soft and stiff as well as dynamically stiffened hydrogels. Histogram of spheroid
diameters for (C) soft, (D) soft-stiff-soft, and (E) stiff hydrogels.
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4.11 Effect of SrtA-mediated Matrix Stiffening on the Chemoresistance
of COLO-357 Cells
Matrix stiffness has been reported to influence PDAC progression by affecting
cell proliferation and chemoresistance [89]. To investigate the role of dynamic ma-
trix stiffening on chemoresistance and EMT, COLO-357 cells were encapsulated in
SrtA-mediated stiffening hydrogels and exposed to gemcitabine, a common PDAC
therapeutic [90]. Cell laden hydrogels were exposed to SrtA treatment on day 3 post
encapsulation, followed by gemcitabine treatment on day 7. As shown in Figure 4.23A,
stiffened hydrogels inhibited spheroid growth while minimally affecting cell viability.
Cell death was observed in soft (∼1 kPa storage modulus) and stiffened (∼4 kPa)
hydrogels treated with gemcitabine compared with the non-treated soft control. How-
ever, the metabolic activity of cells within stiffened hydrogels remained unaffected by
the gemcitabine treatment (Fig 4.23B). On the other hand, the metabolic activity of
the cells in soft hydrogels significantly decreased suggesting gemcitabine both induced
apoptosis and inhibited cell proliferation effectively in softer environments.
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Fig. 4.23. (A) Representative images of COLO-357 cell-laden hydrogels with and
without gemcitabine (1 µM) treatment. Hydrogels were incubated with SrtA on day
3, treated with gemcitabine on day 7 for three days, and imaged both day 7 and day
10 post-encapsulation. (B) Metabolic activity of encapsulated cells pre- (day 7) and
post- (day 10) gemcitabine treatment (N = 6).
In addition to cell viability, the expression of chemoresistance-associated gene
sonic hedgehog (SHH) and YAP target gene ankyrin repeat domain 1 (ANKRD1)
were evaluated after gemcitabine treatment. As shown in Figure 4.24, the enzyme-
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induced stiffening up-regulated the expression of SHH and ANKRD1 (∼5 and ∼70-
fold, respectively) in the cells compared with the control group.
Fig. 4.24. SHH and ANKRD1 expression in COLO-357 cells encapsulated in soft
and stiffened hydrogels treated with gemcitabine (1 µM) for three days (Mean ±
SEM, N=4).
SHH was detected due to its role in tumor size control, CSC stemness, and
chemotherapy resistance [91]. Mechanistically, expression of SHH promotes drug ef-
flux through multi-drug resistance-1 (MDR1) expression [92]. Furthermore, SHH has
been implicated in pre-invasive and invasive phenotypes of PDAC [93], oncogenic Kras
expression [94], and Smo-dependent signaling [95]. Both Kras and Smo-dependent
signaling are significant drivers of pancreatic neoplasia by promoting proliferation,
anti-apoptosis, and tumor environment remodeling [96–98]. Matrix stiffening also
enhances EMT through the YAP/TAZ signaling pathway [89]. The up-regulation
of ANKRD1 expression is consistent with other reports suggesting YAP and TAZ
localization increases with matrix stiffening [99]. Furthermore, gemcitabine may be
preventing tumor suppressor kinase LATS1/2 inhibition of YAP/TAZ by its nucleo-
side analogue activity [100]. However, further research is required to characterize the
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effect of gemcitabine on LATS1/2 activity. Taken together, these data suggest ma-
trix stiffening influences the survival, proliferation, and gene expression of pancreatic
cancer cells through SHH and YAP/TAZ signaling.
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5. SUMMARY AND RECOMMENDATIONS
5.1 Summary
In summary, dynamic enzymatically-crosslinked hydrogels were prepared using
SrtA-mediated transpeptidation and thiol-norbornene photo-click chemistry. The
biophysical properties of the hydrogels can be temporally tuned independent of hy-
drogel formulation through MT-mediated dityrosine formation and SrtA-mediated
transpeptidation. SrtA-mediated crosslinked hydrogels provide highly cytcompatible
cell culture platforms by promoting cell viability, proliferation and morphogenesis in
3D. Moreover, the hydrogels can be rapidly and site-specifically degraded in the pres-
ence of additional SrtA and glycine. MT-mediated dityrosine formation proved to be
an efficient and cytocompatible chemistry for pathophysiologically relevant degrees
of stiffening. In addition to MT-mediated matrix stiffening, SrtA-mediated reversible
stiffening of thiol-ene hydrogels could be achieved by incorporating pendent SrtA sub-
strates. Both matrix stiffening and softening could be tuned by adjusting hydrogel
formulation, enzyme, and soluble glycine concentration.
5.2 Recommendations
Although protease sensitive crosslinkers and cell adhesion ligands were not in-
corporated in this study, future work could include the incorporation of bioactive
peptides (e.g., RGDS or MMP-sensitive linker, GPQGIWGQ) to permit cell-driven
adhesion and degradation. Further, pendent moieties could be attached or removed
by simply incorporating the SrtA substrate, LPXTG or Gn, to the peptide or pro-
tein (e.g., GGG-RGD). This could be utilized not only to study the effect of matrix
stiffening/softening, but also the role of temporally dependent ligand presentation on
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cell fate processes. Due to the orthogonality of both thiol-ene and SrtA-mediated
crosslinking, natural materials (e.g., gelatin and heparin) could be incorporated, fur-
ther enhancing the biological relevancy of the hydrogels.
The reversibility of SrtA transpeptidation is both an advantage and a limitation,
depending on the application. If necessary, the reaction can be rendered irreversible
by synthesizing depsipeptide substrates or peptides that fragment to form an un-
reactive diketopiperazine moiety [101, 102]. This would mitigate the necessity for
excess glycine substrate and would be particularly useful in applications requiring
high-value or minimal reagents for modification. On the other hand, the reversibility
may be desirable for site specific degradation of hydrogels. While this thesis work
demonstrated the degradability of the SrtA-mediated crosslinked hydrogels, a proper
application was not explored. Therefore, another avenue of future work could be us-
ing this degradable crosslinking mechanism to generate and recover tumor spheroids
for future functional and biological characterization studies.
Finally, future studies involving the use of reversible SrtA-mediated stiffening
to further characterize PDAC cells in temporally dynamic matrices should be com-
pleted. Bioactive molecules present in the PDAC desmoplasia such as hyaluronic
acid [103, 104] should be incorporated to study the synergistic effect of biophysi-
cal and biochemical components driving EMT, mesenchymal to epithelial transition
(MET), and chemotherapeutic resistance.
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A. PEG8NB NMR
Fig. A.1. 1H NMR spectrum for PEG8NB (20 kDa). Note that R represents the
pentaerythritol core.
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B. PCR PRIMERS
Table B.1. Gene Sequences Used for Real time PCR.
Gene Sequence Reference
GAPDH
f: GAAGGTGAAGGTCGGAGTC
r: GAAGATGGTGATGGATTTC
Ling H, et al.
Oncogene 2010;29:4543-54
SHH
f: GGAAGCAGCCTCCCGATT
r: CGACTCCAAGGCACATATCCA
Jabari S, et al.
Int. J. Oncol. 2009:45;69-80
ANKRD1
f: GCTGGAGCCCAGATTGAA
r: CTCCACGACATGCCCAGT
Songstad NT, et al.
PLoS One 2014:9:e89559
